Skip to content

Mylan Advair generic rejected by FDA

March 29, 2017

Mylan NV said on Wednesday its application to market a generic copy of GlaxoSmithKline Plc’s blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration.

The drugmaker did not disclose the reason behind the rejection.

Advair has generated more than $1 billion in annual sales since 2001.

https://yhoo.it/2o8VCDa

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: